Citi lowered the firm’s price target on Thermo Fisher (TMO) to $570 from $650 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Coming away from earnings, investor appetite for the sector “remains very light,” primarily due to ongoing U.S. government pressure, the analyst tells investors in a research note. However, Citi sees pockets of the market to be constructive on, such as bioprocessing, where it believes a recovery is underway. Danaher (DHR) is the firm’s top pick.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Strategic Acquisition Boosts Thermo Fisher’s Bioprocessing Position: Analyst Recommends Buy
- Thermo Fisher’s Strategic Acquisition of Solventum: A Path to Growth and Synergy
- Home Depot reports Q4 beat, Zoom gives lower-than-expected outlook: Morning Buzz
- BofA sees acquisition of Solventum’s P&F biz as ‘nice deal’ for Thermo Fisher
- Strategic Acquisition Boosts Thermo Fisher’s Bioproduction Capabilities and Market Position